Recent News
Report Shows that Asbestos Ban Would Benefit Countries Around the World
Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different…
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The…
An Inhalable Gene Therapy is Being Tested for Mesothelioma
An inhalable gene therapy could potentially be approved for use in mesothelioma patients. Researchers in Japan have created two different tumor suppressing drugs that work by targeting genetic mutations. The…
Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)
Primary Outcome Measures Progression-free survival [ Time Frame: From date of randomisation until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to…
Drug Repurposing for Mesothelioma
Research at Temple University is looking at four different drug compounds, all used for noncancerous conditions, for treating mesothelioma. The research is part of a drug repurposing project, which tests…
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma (INTERACT MESO)
Primary Outcome Measures The maximum tolerable dose (MTD) [ Time Frame: After two completed cycles of therapy (each cycle is 1 week) ] The primary endpoint of the study is to determine the maximum…
Immunology and Cytology to Diagnose Mesothelioma
Researchers may have found a better, less invasive way to test for mesothelioma. Normally, a biopsy is done, which requires removing tissue to diagnose mesothelioma, but a new two-part exam…
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Primary Outcome Measures Modification(s) in the immune blood markers of treated subjects on treatment. [ Time Frame: Assessment: between week 4 and 6 after the first dose of the treatment ] Modification(s) in the…
SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer…
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Primary Outcome Measures Determination of ORR for the combination of OT-101 and pembrolizumab in subjects [ Time Frame: approximately 24 months ] modified RECIST (mRECIST; v1.1) Secondary Outcome Measures PFS, DOR and 6-month and…
